The oral version of Novo's GLP-1 is now cleared for obesity treatment in Bahrain, following the UAE as the Gulf's second approval.
Recap by typeshit. Post by @GCCBusinessNews on X.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Analysts point to CagriSema's pending FDA decision, Lilly's EloraTZP hitting 23.3% weight loss in Phase 2b, and mixed petrelintide data as amylin gains momentum.
Chief Health Officer Dr Kerry Chant warns that labels and purity claims prove nothing. Clinicians have reported kidney damage and liver injury linked to products sold as BPC-157 and retatrutide.
Loading…